Creating a Framework for Treating Autoimmune Gastritis-The Case for Replacing Lost Acid.
Level 5 - mechanism / opinion, no new human data
Narrative review presenting theoretical mechanisms and proposals without empirical trial data
PubMed 38474790 · doi:10.3390/nu16050662
What was done
This narrative review synthesizes the physiological roles of gastric acid, details the downstream consequences of hypochlorhydria and achlorhydria in autoimmune gastritis (AIG), and outlines a theoretical rationale for therapeutic gastric re-acidification.
What was found
The abstract reports no empirical trial data, quantitative metrics, or comparative clinical outcomes. It outlines the rationale that betaine hydrochloride (BHCL) could alleviate gastrointestinal symptoms and theoretically reduce hypergastrinemia and N-nitroso compound formation, while supplemental vitamin C could independently limit N-nitroso synthesis.
Why it matters
Patients with autoimmune gastritis frequently experience acid loss and are sometimes inappropriately prescribed acid-suppressing medications; this framework introduces re-acidification as a prospective therapeutic strategy requiring clinical validation.
Limits
This is an unstructured narrative review providing theoretical and mechanistic proposals rather than empirical or clinical trial evidence. No human trials, dosing protocols, safety endpoints, or efficacy data for betaine hydrochloride in autoimmune gastritis are presented.
Cited by
- context Betaine hydrochloride acts as an effective remedy for intestinal gas, indigestion, and acid reflux by acidifying the stomach.